NCT02641379View on ClinicalTrials.gov

A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)

PHASE4CompletedINTERVENTIONAL
Enrollment

737

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Peginterferon alfa-2a

PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n

DRUG

Ribavirin

Ribavirin is available as 200 mg tablets

Trial Locations (21)

1030

Vienna

1090

Vienna

1100

Vienna

1130

Vienna

1140

Vienna

1160

Vienna

2700

Wiener Neustadt

3500

Krems

4010

Linz

4020

Linz

4600

Wels

4910

Ried-innkreis

5020

Salzburg

5110

Oberndorf

6020

Innsbruck

6800

Feldkirch

7350

Oberpullendorf

8020

Graz

8036

Graz

8112

Gratwein

9500

Villach

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02641379 - A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) | Biotech Hunter | Biotech Hunter